NCPC(SH:600812)2022-07-12 16:00Financial Performance - The company's operating revenue for 2021 was approximately ¥10.38 billion, a decrease of 9.64% compared to ¥11.49 billion in 2020[27]. - The net profit attributable to shareholders was ¥18.73 million, down 80.76% from ¥97.32 million in the previous year[27]. - The net cash flow from operating activities increased by 39.63% to ¥1.05 billion, compared to ¥752.15 million in 2020[27]. - The total assets at the end of 2021 were approximately ¥24.93 billion, reflecting a 4.17% increase from ¥23.93 billion in 2020[27]. - The basic earnings per share for 2021 were ¥0.011, a decline of 81.67% from ¥0.060 in 2020[28]. - The company reported a net loss of ¥49.20 million after deducting non-recurring gains and losses, compared to a loss of ¥61.91 million in 2020[27]. - The weighted average return on equity decreased to 0.31% from 1.70% in the previous year[28]. - Total revenue for the company was approximately ¥10.30 billion, a decrease of 9.85% compared to the previous year[64]. - The gross profit margin decreased by 0.25 percentage points to 35.37%[64]. - Total profit amounted to CNY 135 million, reflecting a year-on-year decline of 27.73%[60]. Dividend and Retained Earnings - The company plans to distribute a cash dividend of RMB 0.6 per 10 shares, totaling RMB 102,943,822.2, which represents 549.69% of the net profit attributable to shareholders for the year[6]. - As of December 31, 2021, the company has retained earnings of RMB 714,464,297.92 to be carried forward for future distribution[6]. - The company has not proposed any capital reserve transfer to increase share capital for the current period[6]. Internal Control and Audit - The company reported no significant risks that could materially affect its operations during the reporting period[8]. - The company has identified one major internal control deficiency in its internal control evaluation report for 2021[11]. - The company has received a standard unqualified audit opinion from Zhongtian Yun Accounting Firm for its financial statements[5]. - The company’s financial report has been confirmed for its authenticity, accuracy, and completeness by its board of directors and senior management[4]. - The company has not faced any violations in decision-making procedures regarding external guarantees[8]. Research and Development - The company applied for 41 patents, including 25 invention patents, and was awarded first, second, and third prizes in provincial science and technology progress[36]. - The company has made significant progress in the consistency evaluation of generic drugs, with 11 varieties and 21 specifications passing the evaluation[36]. - The company is focusing on the development of specialty and innovative raw materials to increase the proportion of high-value-added products[45]. - The company is actively pursuing research and development initiatives to enhance its pipeline of injectable antibiotics, aiming for a 15% increase in R&D investment over the next fiscal year[97]. - The company’s R&D investment amounted to 505 million RMB, representing 4.86% of operating revenue, which is in line with the industry average[131]. Market and Product Development - The company is recognized as one of the largest chemical pharmaceutical enterprises in China, with total assets nearing 25 billion yuan and annual sales exceeding 10 billion yuan[42]. - The company is focusing on integrating raw material and formulation development to enhance competitiveness in the pharmaceutical market[90]. - The company is exploring potential mergers and acquisitions to strengthen its position in the pharmaceutical market and expand its product portfolio[97]. - The company aims to enhance its international competitiveness through a unified export platform for formulations[58]. - The company is committed to optimizing its resource allocation and organizational support to align with its strategic goals of marketization, capitalization, and internationalization[152]. Governance and Management - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 10.6479 million yuan[186]. - The company has implemented a performance evaluation system for directors and senior management, which influences their remuneration based on performance results[186]. - The company appointed new independent directors and a chairman through shareholder meetings, indicating a change in governance structure[186]. - The company has a total of 8 key management personnel changes during the reporting period, indicating active management restructuring[186]. - The company’s governance structure has been reinforced with the election of new board members, ensuring alignment with corporate strategy[186]. Operational Efficiency and Cost Management - The company's operating costs decreased by 9.20% to CNY 6.70 billion[60]. - The overall operating cost decreased by 9.50% year-over-year, indicating improved cost management[115]. - The company plans to reduce operational costs by 10% through efficiency improvements in the supply chain[177]. - The company reported a significant reduction in procurement costs for logistics and other trade by 42.63% year-on-year, primarily due to decreased logistics business volume[72]. Future Outlook - The company aims to achieve a revenue target of 38 billion CNY in 2022, focusing on market-oriented and capital-driven strategies[153]. - The management has provided guidance for the next quarter, expecting a revenue growth of approximately 10%[173]. - The company is considering strategic acquisitions to enhance its market position, with a budget of 300 million allocated for potential deals[177]. - The company anticipates a 10% growth in revenue for the upcoming fiscal year, driven by new product launches and market expansion strategies[97].